Kariya Pharmaceuticals Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $591K
Latest Deal Amount
  • Investors
  • 3

Kariya Pharmaceuticals General Information

Description

Developer and researcher of first-in-class drugs designed to slow the progression of neurodegenerative diseases. The company's drug consists of dual incretin receptors, enabling patients to treat Parkinson's and Alzheimer's diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • Ole Maaløes Vej 3
  • 2200 Copenhagen
  • Denmark

Kariya Pharmaceuticals Timeline

20192020
Financing RoundFinancing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kariya Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 10-Dec-2019 $591K 00.000 Completed Startup
2. Accelerator/Incubator 29-May-2019 00.000 Completed Startup
1. Accelerator/Incubator 07-Feb-2019 $1.53M $1.53M Completed Startup
To view Kariya Pharmaceuticals’s complete valuation and funding history, request access »

Kariya Pharmaceuticals Executive Team (3)

Name Title Board Seat Contact Info
Ian Laquian Co-Founder & Chief Executive Officer
Christian Hölscher Co-Founder & Chief Scientific Officer
Mikael Thomsen Ph.D Co-Founder & CDO
To view Kariya Pharmaceuticals’s complete executive team members history, request access »

Kariya Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innovationsfonden Venture Capital Minority 000 0000 000000 0
Copenhagen Bio Science Park Accelerator/Incubator Minority 000 0000 000000 0
BioInnovation Institute (BII) Accelerator/Incubator Minority 000 0000 000000 0
To view Kariya Pharmaceuticals’s complete investors history, request access »